Caris Life Sciences (CAI) priced its IPO at $21.00 – $1.00 above the top of its recently increased range – and sold 23.53 million shares – the number of shares in the prospectus – to raise$494.12 million on Tuesday night, June 17, 2025. The price range was $19.00 to $20.00 – increased on Monday, June 16, from the original price range of $16.00 to $18.00.
Caris Life Sciences, Inc.’s stock (CAI) is expected to start trading today – Wednesday, June 18, 2025 – on the NASDAQ.
At pricing, Caris Life Sciences had a market cap of $5.95 billion.
Caris Life Sciences (CAI) is an AI TechBio precision medicine company focused on cancer, according to the prospectus. The company, founded in 2008, is based in Irving, Texas.
BofA Securities, J.P. Morgan and Goldman Sachs were the lead joint book-runners. Citigroup was also a joint book-runner in a group that included TD Cowen, Evercore ISI and Guggenheim Securities.
Neuberger Berman Investment Advisers LLC, the cornerstone investor, through certain entities had indicated an interest in buying up to $75 million of stock in the IPO, according to the prospectus.
Caris Life Sciences has spent the last 17 years developing and building its “portfolio of comprehensive, proprietary molecular profiling solutions,” the prospectus said. The result is “what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology based on the more than 6.5 million tests we have run on over 849,000 cases, which have generated measurements of over 38 billion molecular markers.”
Oncologists use Caris Life Sciences’ products to diagnose cancer and plan treatment, including the search for clinical trials to help their patients.
Caris Life Sciences said: “Our current commercial product portfolio is focused on oncology and consists of MI Profile, our tissue-based molecular profiling solution that has generated the majority of our revenue to date, and Caris Assure, our novel, universal blood-based molecular profiling solution that was broadly launched in the first quarter of 2024 for therapy selection.”
The company is not profitable. Caris Life Sciences reported a net loss of $248.7 million on revenue of $452.5 million for the 12 months that ended March 31, 2025, according to financial statements in the prospectus.
(For more information about these companies, please check the IPO Calendar and the individual IPO Profiles found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.
Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums) is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions of anyone associated with IPOScoop.com. The SCOOP ratings should not be taken as investment advice. The rating merely reflects the opinion of the professionals at the time of publication and is subject to last-minute changes due to market conditions, changes in a specific offering and other factors, such as changes in the proposed offering terms and the shifting of investor interest in the IPO. The information offered is taken from sources we believe to be reliable, but we cannot guarantee the accuracy.
